Tumor inhibition in xenograft model of diffuse intrinsic pontine glioma via ultra-low and low-frequency magnetic field therapy

A low-frequency (DC-22.05 kHz), time-varying magnetic field signal (rfe_A1A) was tested against the human-derived SF8628 cell line, a diffuse intrinsic pontine glioma (DIPG). This study was done to determine the efficacy and mechanism of action of the rfe_A1A signal, <i>in vitro</i> and <i>in vivo</i>. <i>In vitro</i>, an acellular tubulin polymerization assay and an SF8628 cell culture assay increased tubulin polymerization rates and reduced cell division, respectively. Mouse survival models of DIPG, subsequently exposed to the rfe_A1A signal, demonstrated significantly longer survival times and biomarker changes in Ki67 expression, consistent with a slowdown in cell-division rates. The rfe_A1A signal significantly increased survival time in a DIPG model, a novel strategy tested in clinical studies and compassionate use cases.